We’re pleased to share that the United Leukodystrophy Foundation has shared our press release, marking yet another avenue of informing patients and families affected by Krabbe disease about FBX-101 and our RESKUE Phase 1/2 trial: https://ulf.org/2021/01/fda-clearance-of-investigational-new-drug-for-patients-with-krabbe-disease/
FDA Clearance of Investigational New Drug for Patients with Krabbe Disease
